Ligand Pharmaceuticals
LGND
197 hedge funds and large institutions have $953M invested in Ligand Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 19 increasing their positions, 147 reducing their positions, and 34 closing their positions.
898% more call options, than puts
Call options by funds: $1.74M | Put options by funds: $174K
9% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 34
4% less funds holding
Funds holding: 205 → 197 (-8)
26% less capital invested
Capital invested by funds: $1.28B → $953M (-$327M)
56.65% less ownership
Funds ownership: 141.08% → 84.43% (-57%)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
87% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 147
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.65M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$7.29M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.34M |
| 4 |
SG Americas Securities
New York
|
+$2.46M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$2.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$96.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$67.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$56.9M |
| 4 |
Janus Henderson Group
London,
|
-$49.9M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
-$34.3M |
LGND Hedge Fund Activity: Q4 2022 in Review
197 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2022, worth a combined $953M — down 26% from $1.28B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of LGND and 31 opened new positions — a net loss of 3 holders — while 147 trimmed existing stakes and 19 added.
The largest buyer was Citadel Advisors, adding an estimated $7.65M. The largest seller was BlackRock, cutting an estimated $96.4M.
- 197 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2022, down from 205 in Q3 2022.
- Funds reported $953M of Ligand Pharmaceuticals stock for Q4 2022, down 26% quarter-over-quarter.
- 31 funds opened new Ligand Pharmaceuticals positions in Q4 2022 and 34 closed out, a net change of -3 holders.
- The largest Ligand Pharmaceuticals buyer in Q4 2022 was Citadel Advisors, an estimated $7.65M added.
- The largest Ligand Pharmaceuticals seller in Q4 2022 was BlackRock, an estimated $96.4M sold.
Based on aggregated 13F filings for Q4 2022.